Karina L. Bursch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karina L. Bursch has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Brian Christopher Smith
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, USA
3 shared publications - Raymundo Nuñez
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
3 shared publications - Michael D. Olp
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
2 shared publications - Raul Urrutia
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USA
2 shared publications - Arwa Fallatah
Department of Biology, The Catholic University of America, Washington, District of Columbia, USA
1 shared publication Audrey E. Catlin
Department of Biochemistry , Medical College of Wisconsin , Milwaukee , Wisconsin , USA , mcw.edu
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 9214621
Structural Genomics Defines PBRM1 Bromodomain Variant Function in ccRCC
Polybromo‐1 (PBRM1) modulates chromatin accessibility and transcription via six bromodomains that bind acetyl‐lysine residues on nuclear proteins. PBRM1 variants exist in ~40% of clear cell renal cell carcinoma (ccRCC) cases. PBRM1 loss correlates with improved responses to antiangiogenics and immune checkpoint blockade, which are the standard of care for ccRCC therapy. Missense variants cluster within PBRM1 bromodomains and are present in 16% of ccRCC cases, with unknown impacts on therapeutic response. Since in‐depth biophysical and cellular testing of the hundreds of PBRM1 missense variants reported in ccRCC and other cancer types is intractable, computational approaches can provide actionable variant impact assessments. We employed an integrated structural genomics analysis at the levels of protein sequence (2D), structure (3D), and molecular dynamics (4D) to evaluate the effects of all reported ccRCC‐associated missense variants in the second and fourth bromodomains of PBRM1 (33 total) on molecular fitness (i.e., stability, structural integrity, and ligand binding). We also evaluated the concordance between molecular fitness and biophysical parameters of variant structural integrity (differential scanning fluorimetry, circular dichroism, and 1 H‐NMR spectroscopy) and ligand binding (AlphaScreen and electrophoretic mobility shift assays). Integrated molecular fitness scores correlated with measures of acetylated histone binding, while 3D and integrated molecular fitness scores correlated with measures of thermal stability. This integrated structural genomics analysis accelerates mechanistic understanding of how ccRCC missense variants impact PBRM1 bromodomain structure and function. This knowledge supports future studies correlating specific missense variants with PBRM1 tumor‐suppressive functions and patient responses to antiangiogenics and immune checkpoint blockade to inform ccRCC personalized medicine approaches.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 9214621
Open AccessStructural Genomics Defines PBRM1 Bromodomain Variant Function in ccRCC
Polybromo‐1 (PBRM1) modulates chromatin accessibility and transcription via six bromodomains that bind acetyl‐lysine residues on nuclear proteins. PBRM1 variants exist in ~40% of clear cell renal cell carcinoma (ccRCC) cases. PBRM1 loss correlates with improved responses to antiangiogenics and immune checkpoint blockade, which are the standard of care for ccRCC therapy. Missense variants cluster within PBRM1 bromodomains and are present in 16% of ccRCC cases, with unknown impacts on therapeutic response. Since in‐depth biophysical and cellular testing of the hundreds of PBRM1 missense variants reported in ccRCC and other cancer types is intractable, computational approaches can provide actionable variant impact assessments. We employed an integrated structural genomics analysis at the levels of protein sequence (2D), structure (3D), and molecular dynamics (4D) to evaluate the effects of all reported ccRCC‐associated missense variants in the second and fourth bromodomains of PBRM1 (33 total) on molecular fitness (i.e., stability, structural integrity, and ligand binding). We also evaluated the concordance between molecular fitness and biophysical parameters of variant structural integrity (differential scanning fluorimetry, circular dichroism, and 1 H‐NMR spectroscopy) and ligand binding (AlphaScreen and electrophoretic mobility shift assays). Integrated molecular fitness scores correlated with measures of acetylated histone binding, while 3D and integrated molecular fitness scores correlated with measures of thermal stability. This integrated structural genomics analysis accelerates mechanistic understanding of how ccRCC missense variants impact PBRM1 bromodomain structure and function. This knowledge supports future studies correlating specific missense variants with PBRM1 tumor‐suppressive functions and patient responses to antiangiogenics and immune checkpoint blockade to inform ccRCC personalized medicine approaches.
- Open Access
- 10 February 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108289
Multivalent nucleosome scaffolding by bromodomain and extraterminal domain tandem bromodomains
- 10 February 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108289
Open AccessMultivalent nucleosome scaffolding by bromodomain and extraterminal domain tandem bromodomains
- Open Access
Current Trends in Sirtuin Activator and Inhibitor Development
Sirtuins are NAD+-dependent protein deacylases and key metabolic regulators, coupling the cellular energy state with selective lysine deacylation to regulate many downstream cellular processes. Humans encode seven sirtuin isoforms (Sirt1-7) with diverse subcellular localization and deacylase targets. Sirtuins are considered protective anti-aging proteins since increased sirtuin activity is canonically associated with lifespan extension and decreased activity with developing aging-related diseases. However, sirtuins can also assume detrimental cellular roles where increased activity contributes to pathophysiology. Modulation of sirtuin activity by activators and inhibitors thus holds substantial potential for defining the cellular roles of sirtuins in health and disease and developing therapeutics. Instead of being comprehensive, this review discusses the well-characterized sirtuin activators and inhibitors available to date, particularly those with demonstrated selectivity, potency, and cellular activity. This review also provides recommendations regarding the best-in-class sirtuin activators and inhibitors for practical research as sirtuin modulator discovery and refinement evolve.
Open AccessCurrent Trends in Sirtuin Activator and Inhibitor Development
Sirtuins are NAD+-dependent protein deacylases and key metabolic regulators, coupling the cellular energy state with selective lysine deacylation to regulate many downstream cellular processes. Humans encode seven sirtuin isoforms (Sirt1-7) with diverse subcellular localization and deacylase targets. Sirtuins are considered protective anti-aging proteins since increased sirtuin activity is canonically associated with lifespan extension and decreased activity with developing aging-related diseases. However, sirtuins can also assume detrimental cellular roles where increased activity contributes to pathophysiology. Modulation of sirtuin activity by activators and inhibitors thus holds substantial potential for defining the cellular roles of sirtuins in health and disease and developing therapeutics. Instead of being comprehensive, this review discusses the well-characterized sirtuin activators and inhibitors available to date, particularly those with demonstrated selectivity, potency, and cellular activity. This review also provides recommendations regarding the best-in-class sirtuin activators and inhibitors for practical research as sirtuin modulator discovery and refinement evolve.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S705-S706
Abstract 1294: Cancer-associated missense mutations in the tumor suppressor Polybromo-1 variably affect protein stability and function
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S705-S706
Open AccessAbstract 1294: Cancer-associated missense mutations in the tumor suppressor Polybromo-1 variably affect protein stability and function
- Open Access
- 7 June 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (6) , 1083-1085
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH‐inhibitor therapy for AML
- 7 June 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (6) , 1083-1085
Open AccessRevisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH‐inhibitor therapy for AML
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Cell Adhesion & Migration
- Vol. 15 (1) , 1-17
Keratin 19 maintains E-cadherin localization at the cell surface and stabilizes cell-cell adhesion of MCF7 cells
A cytoskeletal protein keratin 19 (K19) is highly expressed in breast cancer but its effects on breast cancer cell mechanics are unclear. In MCF7 cells where K19 expression is ablated, we found that K19 is required to maintain rounded epithelial-like shape and tight cell-cell adhesion. A loss of K19 also lowered cell surface E-cadherin levels. Inhibiting internalization restored cell-cell adhesion of KRT19 knockout cells, suggesting that E-cadherin internalization contributed to defective adhesion. Ultimately, while K19 inhibited cell migration and invasion, it was required for cells to form colonies in suspension. Our results suggest that K19 stabilizes E-cadherin complexes at the cell membrane to maintain cell-cell adhesion which inhibits cell invasiveness but provides growth and survival advantages for circulating tumor cells.
- 1 January 2021
- Published by Taylor & Francis in Cell Adhesion & Migration
- Vol. 15 (1) , 1-17
Open AccessKeratin 19 maintains E-cadherin localization at the cell surface and stabilizes cell-cell adhesion of MCF7 cells
A cytoskeletal protein keratin 19 (K19) is highly expressed in breast cancer but its effects on breast cancer cell mechanics are unclear. In MCF7 cells where K19 expression is ablated, we found that K19 is required to maintain rounded epithelial-like shape and tight cell-cell adhesion. A loss of K19 also lowered cell surface E-cadherin levels. Inhibiting internalization restored cell-cell adhesion of KRT19 knockout cells, suggesting that E-cadherin internalization contributed to defective adhesion. Ultimately, while K19 inhibited cell migration and invasion, it was required for cells to form colonies in suspension. Our results suggest that K19 stabilizes E-cadherin complexes at the cell membrane to maintain cell-cell adhesion which inhibits cell invasiveness but provides growth and survival advantages for circulating tumor cells.